TPTX

Turning Point Therapeutics, Inc.

A San Diego biopharmaceutical company developing precision cancer medicines called kinase inhibitors that target specific gene mutations fueling tumor growth. Its lead experimental drug, repotrectinib, was designed for patients with ROS1- and TRK-driven cancers, including non-small cell lung cancer. Founded in 2013, the company was acquired by Bristol Myers Squibb in 2022; the name reflects its goal of marking a turning point in treatment for hard-to-treat cancers.

No 8-K or 6-K filings recorded.